PMV Pharmaceuticals, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for PMV Pharmaceuticals, Inc. (PMVP), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are PMVP insiders buying or selling?
In the last 12 months, PMV Pharmaceuticals, Inc. insiders reported 0 open-market purchases ($0) and 1 sale ($1.5M) — net selling of $1.5M. Since September 2020, Trabud has recorded 72 Form 4 filings for PMVP: 8 buys ($72.4M) and 64 sells ($61.9M).
Source: SEC EDGAR Form 4
Key Statistics (September 2020 – Oct 27, 2025)
Total Form 4 filings
72
SEC EDGAR
Insider filers
16
Insider buys (8)
$72.4M
Insider sells (64)
$61.9M
Insider sentiment
Net buyingNet insider flow of $10.4M in net buying since September 2020, and $1.5M in net selling over the last 12 months.
Recent PMVP insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 27, 2025 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 1.0M | $1.52 | $1.5M | SEC ↗ |
| Sep 12, 2025 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 500.0K | $1.80 | $900.0K | SEC ↗ |
| Jul 3, 2025 | Robert Ticktin | General Counsel & COO | Sale | 23.2K | $1.06 | $24.7K | SEC ↗ |
| Jul 3, 2025 | Deepika Jalota | Chief Development Officer | Sale | 33.1K | $1.06 | $35.2K | SEC ↗ |
| Jul 3, 2025 | Michael Carulli | Chief Financial Officer | Sale | 28.2K | $1.06 | $30.1K | SEC ↗ |
| Jul 3, 2025 | David Henry Mack | President and CEO | Sale | 58.4K | $1.06 | $62.2K | SEC ↗ |
| Sep 12, 2024 | Deepika Jalota | Chief Development Officer | Sale | 7.2K | $1.50 | $10.9K | SEC ↗ |
| Sep 12, 2024 | Michael Carulli | Chief Financial Officer | Sale | 2.9K | $1.50 | $4.3K | SEC ↗ |
| Nov 24, 2023 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 87.8K | $2.23 | $195.8K | SEC ↗ |
| Sep 18, 2023 | Deepika Jalota | Chief Development Officer | Sale | 4.1K | $6.62 | $27.2K | SEC ↗ |
| Sep 18, 2023 | Leila Alland | Chief Medical Officer | Sale | 6.3K | $6.62 | $41.6K | SEC ↗ |
| May 31, 2022 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 26.3K | $15.93 | $418.2K | SEC ↗ |
| Mar 31, 2022 | ORBIMED ADVISORS LLC | 10% Owner | Sale | 474.5K | $21.63 | $10.3M | SEC ↗ |
| Oct 8, 2021 | Thilo Schroeder | Director | Sale | 800 | $30.15 | $24.1K | SEC ↗ |
| Oct 5, 2021 | Thilo Schroeder | Director | Sale | 14.6K | $30.09 | $439.8K | SEC ↗ |
| Sep 29, 2021 | Thilo Schroeder | Director | Sale | 7.5K | $30.06 | $224.3K | SEC ↗ |
| Sep 24, 2021 | Thilo Schroeder | Director | Sale | 100 | $30.00 | $3.0K | SEC ↗ |
| Sep 24, 2021 | Arnold J Levine | Director | Sale | 3.5K | $30.00 | $105.0K | SEC ↗ |
| Sep 21, 2021 | Thilo Schroeder | Director | Sale | 711 | $30.03 | $21.4K | SEC ↗ |
| Sep 14, 2021 | Thilo Schroeder | Director | Sale | 70.8K | $30.41 | $2.2M | SEC ↗ |
| Sep 10, 2021 | Leila Alland | Chief Medical Officer | Sale | 100 | $30.25 | $3.0K | SEC ↗ |
| Sep 8, 2021 | Leila Alland | Chief Medical Officer | Sale | 3.9K | $30.25 | $118.0K | SEC ↗ |
| Sep 3, 2021 | Thilo Schroeder | Director | Sale | 46.9K | $30.25 | $1.4M | SEC ↗ |
| Aug 30, 2021 | Thilo Schroeder | Director | Sale | 58.8K | $30.45 | $1.8M | SEC ↗ |
| Aug 26, 2021 | Thilo Schroeder | Director | Sale | 51.9K | $30.87 | $1.6M | SEC ↗ |
Showing the 25 most recent of 72 Form 4 filings for PMV Pharmaceuticals, Inc..
Most active PMVP insiders
- Thilo Schroeder27 filings
- Leila Alland8 filings
- ORBIMED ADVISORS LLC6 filings
- Arnold J Levine5 filings
- David Henry Mack4 filings
Ask anything about PMVP insider activity
Use Trabud's AI agent to query PMV Pharmaceuticals, Inc.'s Form 4 history in plain English — "Show me PMVP CEO purchases this year" or compare it against any other ticker.
Open the AI agentPMVP insider trading FAQ
Are PMV Pharmaceuticals, Inc. insiders buying or selling?
In the last 12 months, PMV Pharmaceuticals, Inc. insiders reported 0 open-market purchases ($0) and 1 sale ($1.5M) — net selling of $1.5M. Since September 2020, Trabud has recorded 72 Form 4 filings for PMVP: 8 buys ($72.4M) and 64 sells ($61.9M). Over the full record that is net buying of $10.4M.
How many insiders trade PMVP stock?
16 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for PMV Pharmaceuticals, Inc.. The most recent filing was accepted on Oct 27, 2025.
Where does Trabud get PMVP insider trading data?
All PMVP insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.